{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:10:55Z","timestamp":1787238655733,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001785","name":"Flinders University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pathol.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T08:12:29Z","timestamp":1597911149000},"page":"635-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Malignant mesothelioma in situ: diagnostic and clinical considerations"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-7141","authenticated-orcid":false,"given":"Emily","family":"Pulford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-4714","authenticated-orcid":false,"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2020.06.010_bib1","first-page":"151","article-title":"The concept of mesothelioma in situ: implications for diagnosis and histogenesis","volume":"9","author":"Whitaker","year":"1992","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib2","series-title":"Tumors of the Serosal Membranes","author":"Churg","year":"2006"},{"key":"10.1016\/j.pathol.2020.06.010_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00428-005-0005-4","article-title":"Chromosomal alterations in early stages of malignant mesotheliomas","volume":"447","author":"Simon","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2020.06.010_bib4","series-title":"The Mesothelium of the Rat and its Response to Injury","author":"Whitaker","year":"1983"},{"key":"10.1016\/j.pathol.2020.06.010_bib5","series-title":"Malignant Mesothelioma","first-page":"25","article-title":"The pathobiology of the mesothelium","author":"Whitaker","year":"1992"},{"key":"10.1016\/j.pathol.2020.06.010_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/path.1711450204","article-title":"Mesothelial healing: morphological and kinetic investigations","volume":"145","author":"Whitaker","year":"1985","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcp\/110.3.397","article-title":"Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review","volume":"110","author":"Henderson","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<583::AID-CNCR22>3.0.CO;2-X","article-title":"The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses","volume":"82","author":"Wolanski","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2020.06.010_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/1742-6413.170726","volume":"12","author":"Hjerpe","year":"2015","journal-title":"Cytojournal"},{"key":"10.1016\/j.pathol.2020.06.010_bib10","series-title":"Malignant Mesothelioma","first-page":"140","article-title":"Unusual histological types and anatomic sites of mesothelioma","author":"Henderson","year":"1992"},{"issue":"Suppl","key":"10.1016\/j.pathol.2020.06.010_bib11","first-page":"166A","article-title":"Expression of desmin and smooth muscle actin in mesothelial hyperplasia and mesothelioma","volume":"169","author":"Scoones","year":"1993","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0046-8177(94)90243-7","article-title":"Desmin and neural marker expression in mesothelial cells and mesotheliomas","volume":"25","author":"Hurlimann","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1309\/AJCP5KNL7QTELLYI","article-title":"Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells","volume":"141","author":"Minato","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jcp.2008.061887","article-title":"An EMA negative, desmin positive malignant mesothelioma: limitations of immunohistochemistry?","volume":"62","author":"Salman","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/00000478-200110000-00012","article-title":"Well-differentiated papillary mesothelioma","volume":"25","author":"Butnor","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2020.06.010_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F","article-title":"The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis","volume":"189","author":"Cury","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib18","doi-asserted-by":"crossref","first-page":"1310478","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.pathol.2020.06.010_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pathol.2020.06.010_bib21","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2020.06.010_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pathol.2020.06.010_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pathol.2020.06.010_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2020.06.010_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2020.06.010_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2020.06.010_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1164\/ajrccm.161.2.9904123","article-title":"Talc induces apoptosis in human malignant mesothelioma cells in\u00a0vitro","volume":"161","author":"Nasreen","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pathol.2020.06.010_bib32","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thx.31.1.15","article-title":"Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients","volume":"31","author":"Butchart","year":"1976","journal-title":"Thorax"},{"key":"10.1016\/j.pathol.2020.06.010_bib34","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2020.06.010_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-015-0040-5","article-title":"BAP1 hereditary cancer predisposition syndrome: a case report and review of literature","volume":"3","author":"Klebe","year":"2015","journal-title":"Biomark Res"},{"key":"10.1016\/j.pathol.2020.06.010_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2020.06.010_bib37","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2020.06.010_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.humpath.2018.05.001","article-title":"BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma","volume":"79","author":"Lee","year":"2018","journal-title":"Hum Pathol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520308722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520308722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:26:37Z","timestamp":1758471997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302520308722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0031302520308722"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2020.06.010","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant mesothelioma in situ: diagnostic and clinical considerations","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}